Blood: Supplementing IL-2 improves prognosis in patients with ispecificatic aplastic anemia

Iexclusiveirerere anemia (AA) has two main characteristics: autoimmune response to hematopoietic stem cells/progenitor cells and regulatory Tregs defectsResearchers have previously demonstrated a reduction in a specific subgroup of Treg in AA patients, which can predict patients' response to immunosuppressive therapyThe purpose of this study is to identify the mechanisms of imbalance in Treg subgroups and to determine the potential for therapeutic interventionsnow, researchers have identified two mechanisms that cause confusion in the composition of Treg in Patients With AAIApoptosis of FasL-mediated ligand interactions;current researchers have confirmed that an increase in IL-2 can overcome these mechanismsInterestingly, when high concentrations of IL-2 are added to in vitro cultured Treg, Treg from AA patient sources can be amplifiedAmplification cells express high levels of p-BCL2;p-BCL2 make them resistant to apoptosisresearchers further tested the function and stability of amplification AA Tregs cells through the transplanted tumor mouse model, and found that these Tregs cells inhibited the macro-clinical characteristics and tissue manifestations of T-cell-mediated grafts against host diseaseThese Tregs maintain their inhibition properties and phenotype in high-inflammatory environmentsthe results of this study provide an idea for an in-depth understanding of the mechanism of Treg cell reduction in AA, and identify new targets with therapeutic intervention potentialOn the basis of conventional immunosuppressive therapy, supplementing with high concentrations of IL-2 Treg in vitro amplification culture or directly to IL-2 can improve the clinical efficacy of AA patients